Background We did a randomised controlled trial to assess the benefit of maintenance
infliximab therapy in patients with active Crohn's disease who respond to a single infusion of …

Background Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor
α, is an established treatment for Crohn's disease but not ulcerative colitis. Methods Two …

Guidelines for clinical practice are intended to suggest preferable approaches to particular
medical problems as established by interpretation and collation of scientifically valid research…

Background & Aims: Long-term safety data for infliximab and other therapies in Crohn’s
disease (CD) are needed. Methods: We prospectively evaluated patients for prespecified safety-…

Background & aims : This analysis of Crohn’s disease patients treated with infliximab in
ACCENT I compared episodic and scheduled treatment strategies under conditions that simulate …

Crohn's disease is an idiopathic inflammatory disorder of unknown etiology with genetic,
immunologic, and environmental influences. The incidence of Crohn's disease has steadily …

BACKGROUND & AIMS: In the Active Ulcerative Colitis Trial (ACT)-1 and ACT-2, patients with
ulcerative colitis treated with infliximab were more likely than those given placebo to have …

OBJECTIVES: The objective of this study was to contribute long-term safety data for infliximab
and other therapies in Crohn's disease (CD). METHODS: We prospectively evaluated CD …

Background The Mayo score and a noninvasive 9-point partial Mayo score are used as
outcome measures for clinical trials assessing therapy for ulcerative colitis (UC). There are …

Background & Aims: Infliximab is effective in closing fistulas in patients with Crohn’s disease.
We examined the effect of infliximab maintenance treatment on hospitalizations, surgeries, …